These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 29413968)
1. Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. Schiefer M; Hendriks LEL; Dinh T; Lalji U; Dingemans AC Eur J Cancer; 2018 Mar; 91():92-98. PubMed ID: 29413968 [TBL] [Abstract][Full Text] [Related]
2. Long QT syndrome after using EGFR-TKIs in older patients with advanced non-small cell lung cancer. Byun JY; Han S; Qdaisat A; Park C Expert Opin Drug Saf; 2024 Aug; 23(8):1007-1015. PubMed ID: 38088244 [TBL] [Abstract][Full Text] [Related]
3. Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma. Bardaro F; Stirpe E J Oncol Pharm Pract; 2022 Jun; 28(4):989-994. PubMed ID: 35037771 [TBL] [Abstract][Full Text] [Related]
4. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS; N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359 [TBL] [Abstract][Full Text] [Related]
6. Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. Provencio M; Serna-Blasco R; Franco F; Calvo V; Royuela A; Auglytė M; Sánchez-Hernández A; de Julián Campayo M; García-Girón C; Dómine M; Blasco A; Sánchez JM; Oramas J; Bosch-Barrera J; Sala MÁ; Sereno M; Ortega AL; Chara L; Hernández B; Padilla A; Coves J; Blanco R; Balsalobre J; Mielgo X; Bueno C; Jantus-Lewintre E; Molina-Vila MÁ; Romero A Eur J Cancer; 2021 May; 149():61-72. PubMed ID: 33831609 [TBL] [Abstract][Full Text] [Related]
7. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. Bollinger MK; Agnew AS; Mascara GP J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936 [TBL] [Abstract][Full Text] [Related]
8. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the Furuta H; Uemura T; Yoshida T; Kobara M; Yamaguchi T; Watanabe N; Shimizu J; Horio Y; Kuroda H; Sakao Y; Yatabe Y; Hida T Anticancer Res; 2018 Sep; 38(9):5231-5237. PubMed ID: 30194172 [TBL] [Abstract][Full Text] [Related]
10. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163 [TBL] [Abstract][Full Text] [Related]
11. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. Oztan A; Fischer S; Schrock AB; Erlich RL; Lovly CM; Stephens PJ; Ross JS; Miller V; Ali SM; Ou SI; Raez LE Lung Cancer; 2017 Sep; 111():84-87. PubMed ID: 28838405 [TBL] [Abstract][Full Text] [Related]
12. Overall Survival with Osimertinib in Untreated, Ramalingam SS; Vansteenkiste J; Planchard D; Cho BC; Gray JE; Ohe Y; Zhou C; Reungwetwattana T; Cheng Y; Chewaskulyong B; Shah R; Cobo M; Lee KH; Cheema P; Tiseo M; John T; Lin MC; Imamura F; Kurata T; Todd A; Hodge R; Saggese M; Rukazenkov Y; Soria JC; N Engl J Med; 2020 Jan; 382(1):41-50. PubMed ID: 31751012 [TBL] [Abstract][Full Text] [Related]
13. Safety of osimertinib in EGFR-mutated non-small cell lung cancer. Mezquita L; Varga A; Planchard D Expert Opin Drug Saf; 2018 Dec; 17(12):1239-1248. PubMed ID: 30457891 [TBL] [Abstract][Full Text] [Related]
14. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma. Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial. Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885 [TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma. Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma. Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596 [TBL] [Abstract][Full Text] [Related]
18. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270 [TBL] [Abstract][Full Text] [Related]
19. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report. Zhou Y; Qi X; Wang Y; Dong H; Zhuang L Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042 [TBL] [Abstract][Full Text] [Related]
20. Osimertinib for the treatment of patients with Alsharedi M; Bukamur H; Elhamdani A Drugs Today (Barc); 2018 Jun; 54(6):369-379. PubMed ID: 29998228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]